With the help of some of nature’s best engineers, NIBIB-funded researchers have developed technology to regrow damaged facial nerves.

Releasing a drug selectively in specific locations in the body, including the brain, has been challenging. Researchers at the University of Utah have tackled the problem by designing ultrasound-sensitive nanoparticles that release a drug at the targeted site when activated by focused ultrasound.

NIH has awarded more than $4 million in funds and support services to three diagnostic technology developers as part of RADx ® Tech’s Advanced Platforms for HIV Viral Load Monitoring program.

Researchers use multiorgan tissue chips to study the impacts of space radiation on human physiology to support the astronauts of tomorrow.

With their eclectic mix of mutations, tumors often survive drug treatment. In a new study, researchers found a way to use cancer’s evolutionary potential against it, destroying drug-resistant tumors in animals.

NIBIB has designed an initiative called Enhancing Biomedical Engineering, Imaging, and Technology Acceleration (eBEITA) at HBCUs. Recently, NIBIB made its first round of eBEITA grants to two HBCUs.

Researchers are developing preclinical microgrippers that could be deployed throughout the upper urinary tract to grab tiny pieces of tissue and facilitate early detection of disease.

NIBIB bioengineer Kaitlyn Sadtler has flourished as a leader of many impactful, interdisciplinary studies. For her role in shaping the future of medical research, TIME magazine has named Kaitlyn Sadtler to the TIME100 Next 2024 List.

NIBIB-funded researchers are working to bring in vivo gene editing to the fore. Through rational engineering of lipid nanoparticles, this collaborative team developed a way to effectively target specific organs in the body to precisely deliver therapeutic cargo, including gene-editing molecules. Their research demonstrated that a one-time treatment with their nanoparticles resulted in durable gene editing in mouse lungs for nearly two years. Further, their technique showed promise in correcting a mutation present in a currently untreatable form of cystic fibrosis in several models of the disease.